Publication: Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen
Authors
Wculek, Stefanie K. ; Amores Iniesta, Joaquín ; Conde Garrosa, Ruth ; Kouili, Sofía C. ; Melero, Ignacio ; Sancho, David
item.page.secondaryauthor
item.page.director
Publisher
BMJ Publishing Group
publication.page.editor
publication.page.department
DOI
https://doi.org/10.1186/s40425-019-0565-5
item.page.type
info:eu-repo/semantics/article
Description
© The Author(s) 2019. This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by/4.0/
This document is the Published version of a Published Work that appeared in final form in Journal for ImmunoTherapy of Cancer. To access the final edited and published work see https://doi.org/10.1186/s40425-019-0565-5
Abstract
The manipulation of dendritic cells (DCs) for cancer vaccination has not reached its full potential, despite the revolution in cancer immunotherapy. DCs are fundamental for CD8+ T cell activation, which relies on cross-presentation of exogenous antigen on MHC-I and can be fostered by immunogenic cancer cell death. Translational and clinical research has focused on in vitro-generated monocyte-derived DCs, while the vaccination efficacy of natural conventional type 1 DCs (cDC1s), which are associated with improved anti-tumor immunity and specialize on antigen cross-presentation, remains unknown.
publication.page.subject
Citation
item.page.embargo
Collections
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by/4.0/